SCHEMBL2881728

SCHEMBL2881728

CC(C)(C)C1C(OS(C)(=O)=O)CN1C(=O)O

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2933887 0.89
SCHEMBL21585592 0.85
SCHEMBL30327706 0.84 NR1H2 (0.36)
SCHEMBL1791330 0.84 HSD17B10 (0.30)
SCHEMBL1786234 0.84 HSD17B10 (0.30)
SCHEMBL344780 0.84 HSD17B10 (0.30)
SCHEMBL18393475 0.84 HSD17B10 (0.30)
SCHEMBL344781 0.84 HSD17B10 (0.30)
SCHEMBL2586890 0.81 HSD17B10 (0.36)
SCHEMBL18007258 0.81 HSD17B10 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107532229-B Process for leaching metal sulphides with an agent having a thiocarbonyl function 不列颠哥伦比亚大学 2021-10-08 CN claimed
EP-3722298-B1 PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR OSCOTEC INC (KR) 2023-08-02 EP disclosed
CN-110352256-B Process for leaching metal sulphides with an agent having a thiocarbonyl function 捷迪资源有限责任公司 2023-01-10 CN disclosed
US-11370796-B2 Substituted pyrazoles as LRRK2 inhibitors OSCOTEC INC. (KR) 2022-06-28 US disclosed
US-20210363144-A1 PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR OSCOTEC INC. (KR) 2021-11-25 US disclosed
EP-3722298-A1 PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR Oscotec Inc. (KR) 2020-10-14 EP disclosed
EP-2807162-B1 SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF Bayer Pharma AG (DE) 2017-06-07 EP disclosed
EP-2590969-B1 Therapeutic agents 976 ASTRAZENECA AB (SE) 2014-10-15 EP disclosed
US-20100261699-A1 N-PYRAZOLE-2-PYRIDINE CARBOXAMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
EP-2236507-A1 N-PYRAZOLE-2-PYRIDINECARBOXAMIDE DERIVATIVE Banyu Pharmaceutical Co., Ltd. (JP) 2010-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210363144-A1 PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR LRRK2, PARK7, WEE1 POLB 916/4885
US-11370796-B2 Substituted pyrazoles as LRRK2 inhibitors LRRK2, PARK7, PAK3 POLB 1894/4885
US-20100261699-A1 N-PYRAZOLE-2-PYRIDINE CARBOXAMIDE DERIVATIVE GCKR, GPR119, GCK POLB 4274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.